卵巢癌中癌症干细胞样细胞标志物乙醛脱氢酶-1(ALDH1)的预后影响:一项Meta分析
本Meta分析通过检索PubMed、MEDLINE和Scopus(2018年1月)纳入13项研究共1885例卵巢癌患者,评估ALDH1表达与预后及临床病理特征的关系。结果显示ALDH1高表达与较差的5年总生存(OR=3.46;95%CI:1.61-7.42;P=0.001)和5年无进展生存(OR=2.14;95%CI:1.11-4.13;P=0.02)显著相关,而与肿瘤组织学、FIGO分期、肿瘤分级、淋巴结状态及诊断时年龄无相关性。
要点
- ALDH1高表达与卵巢癌患者较差的5年总生存显著相关(OR=3.46;95%CI:1.61-7.42;P=0.001)。
- ALDH1高表达与卵巢癌患者较差的5年无进展生存显著相关(OR=2.14;95%CI:1.11-4.13;P=0.02)。
- ALDH1表达与肿瘤组织学、FIGO分期、肿瘤分级、淋巴结状态及诊断时年龄均无显著相关性。
核心结论
- 基于现有证据,本Meta分析显示ALDH1高表达与卵巢癌患者较差的OS和PFS相关。
研究设计与样本
- 通过PubMed、MEDLINE和Scopus数据库于2018年1月进行电子检索,检索词为「ovarian cancer」AND「immunohistochemistry」AND「aldehyde dehydrogenase-1」OR「ALDH1」OR「cancer stem cell」。
- 共检索到233项研究,最终纳入13项符合全部选择标准的研究,共包括1885例患者。
主要发现
- ALDH1高表达与较差的5年OS显著相关(OR=3.46;95%CI:1.61-7.42;P=0.001,随机效应模型)。
- ALDH1高表达与较差的5年PFS显著相关(OR=2.14;95%CI:1.11-4.13;P=0.02,随机效应模型)。
- ALDH1表达与肿瘤组织学无相关性(OR=0.60;95%CI:0.36-1.02;P=0.06,随机效应模型)。
- ALDH1表达与FIGO分期无相关性(OR=0.65;95%CI:0.33-1.30;P=0.22,随机效应模型)。
- ALDH1表达与肿瘤分级无相关性(OR=0.76;95%CI:0.40-1.45;P=0.41,随机效应模型)。
关键数值与推荐
- ALDH1高表达与5年OS的OR=3.46(95%CI:1.61-7.42;P=0.001,随机效应模型)。
- ALDH1高表达与5年PFS的OR=2.14(95%CI:1.11-4.13;P=0.02,随机效应模型)。
- ALDH1表达与肿瘤组织学的OR=0.60(95%CI:0.36-1.02;P=0.06,随机效应模型)。
- ALDH1表达与FIGO分期的OR=0.65(95%CI:0.33-1.30;P=0.22,随机效应模型)。
- ALDH1表达与肿瘤分级的OR=0.76(95%CI:0.40-1.45;P=0.41,随机效应模型)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the association of cancer stem cell biomarker aldehyde dehydrogenase-1 (ALDH1) with ovarian cancer patients' prognosis and clinico-pathological characteristics. METHODS: The electronic searches were performed in January 2018 through the databases PubMed, MEDLINE and Scopus by searching the terms: "ovarian cancer" AND "immunohistochemistry" AND ["aldehyde dehydrogenase-1" OR "ALDH1" OR "cancer stem cell"]. Studies evaluating the impact of ALDH1 expression on ovarian cancer survival and clinico-pathological variables were selected. RESULTS: 233 studies were retrieved. Thirteen studies including 1885 patients met all selection criteria. ALDH1-high expression was found to be significantly associated with poor 5-year OS (OR = 3.46; 95% CI: 1.61-7.42; P = 0.001, random effects model) and 5-year PFS (OR = 2.14; 95% CI: 1.11-4.13; P = 0.02, random effects model) in ovarian cancer patients. No correlation between ALDH1 expression and tumor histology (OR = 0.60; 95% CI: 0.36-1.02; P = 0.06, random effects model), FIGO Stage (OR = 0.65; 95% CI: 0.33-1.30; P = 0.22, random effects model), tumor grading (OR = 0.76; 95% CI: 0.40-1.45; P = 0.41, random effects model) lymph nodal status (OR = 2.05; 95% CI: 0.81-5.18; P = 0.13, random effects model) or patients' age at diagnosis (OR = 0.83; 95% CI: 0.54-1.29; P = 0.41, fixed effects model) was identified. CONCLUSIONS: Basing on the available evidence, this meta-analysis showed that high levels of ALDH1 expression correlate with worse OS and PFS in ovarian cancer patients.
引用
- Ruscito I, Darb-Esfahani S, Kulbe H, et al. The prognostic impact of cancer stem-like cell biomarker aldehyde dehydrogenase-1 (ALDH1) in ovarian cancer: A meta-analysis. Gynecol Oncol. 2018. PMID: 29753392. doi:10.1016/j.ygyno.2018.05.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。